| pubmed-article:12601106 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12601106 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
| pubmed-article:12601106 | lifeskim:mentions | umls-concept:C0221198 | lld:lifeskim |
| pubmed-article:12601106 | lifeskim:mentions | umls-concept:C0024485 | lld:lifeskim |
| pubmed-article:12601106 | lifeskim:mentions | umls-concept:C1979874 | lld:lifeskim |
| pubmed-article:12601106 | lifeskim:mentions | umls-concept:C0243144 | lld:lifeskim |
| pubmed-article:12601106 | lifeskim:mentions | umls-concept:C1719822 | lld:lifeskim |
| pubmed-article:12601106 | lifeskim:mentions | umls-concept:C1272706 | lld:lifeskim |
| pubmed-article:12601106 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:12601106 | pubmed:dateCreated | 2003-2-25 | lld:pubmed |
| pubmed-article:12601106 | pubmed:abstractText | One of the diagnostic imaging hallmarks of MS is the uptake of IV administered contrast material in new lesions in the brain, signaling blood-brain barrier breakdown and active inflammation. Many clinical drug trials are designed based on the assumption that lesion enhancement on MRI remains visible on average for 1 month. For practical reasons, few serial MRI studies of patients with MS have been performed at intervals shorter than 4 weeks. | lld:pubmed |
| pubmed-article:12601106 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12601106 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12601106 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12601106 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12601106 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12601106 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12601106 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12601106 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12601106 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:12601106 | pubmed:issn | 1526-632X | lld:pubmed |
| pubmed-article:12601106 | pubmed:author | pubmed-author:WeinerHoward... | lld:pubmed |
| pubmed-article:12601106 | pubmed:author | pubmed-author:JoleszFerenc... | lld:pubmed |
| pubmed-article:12601106 | pubmed:author | pubmed-author:GuttmannCharl... | lld:pubmed |
| pubmed-article:12601106 | pubmed:author | pubmed-author:CottonFrancoi... | lld:pubmed |
| pubmed-article:12601106 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:12601106 | pubmed:day | 25 | lld:pubmed |
| pubmed-article:12601106 | pubmed:volume | 60 | lld:pubmed |
| pubmed-article:12601106 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12601106 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12601106 | pubmed:pagination | 640-6 | lld:pubmed |
| pubmed-article:12601106 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:meshHeading | pubmed-meshheading:12601106... | lld:pubmed |
| pubmed-article:12601106 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12601106 | pubmed:articleTitle | MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. | lld:pubmed |
| pubmed-article:12601106 | pubmed:affiliation | Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. | lld:pubmed |
| pubmed-article:12601106 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12601106 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12601106 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12601106 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12601106 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12601106 | lld:pubmed |
